In premarket trade, Vyant Bio Inc. (VYNT) shares are up 13.33% to $4.08. Vyant stock closed Friday with a loss of -2.70%, closing at $3.60. The VYNT stock volume was 0.73 million shares, which was less than the average daily volume of 1.27 million shares over the past 50 days. In the past week, VYNT stock has declined by -1.37%, with a rise of 29.50% in the past 12 months.
VYNT stock has declined -14.49% over the past three months while shedding -8.86% over the past six months. In addition, the company’s market cap stands at $40.72 million and its outstanding shares stand at 3.55 million. VYNT stock seems to be gaining on a recent collaboration for protein therapeutics.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Read More
What was the collaboration?
The Vyant Bio team is rapidly emerging as one of the leading biotechnology drug discovery companies. Aside from data and science expertise (both in biology and chemistry), engineering expertise, and regulatory expertise, VYNT is rapidly identifying small and large molecule medicinal compounds and derisking decision making as a result of multiple in vitro and in vivo modalities. Utilizing these approaches, Vyant Bio is able to maximize the value of compounds for the development of therapeutics and new treatments. Partnering with others, Vyant Bio further develops and commercializes products for patients.
An agreement came last week between Vyant and two biotechnology companies which will seek to reduce the development risk of small protein therapeutics.
As a result of a partnership with Ordas Bio and Cellaria Inc, Vyant is unveiling a biologically derived model that will enable fast iteration and rapid development of therapeutics with artificial intelligence. This project aims to provide an early detection system for a drug’s efficacy in different patient cohorts, prior to clinical trials.
How does it work?
This partnership builds on each company’s unique strengths in the areas of formulation design, manufacturing, and testing of small biomarkers derived from whole-genome sequences of patient populations.
